Prot #X052132: An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects with Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Who Each Successfully Completed Either the X052130 or the X052131 Study or